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Abstract
Objective To describe individual patient preferences for
Personalised Trials and to identify factors and conditions
associated with patient preferences.
Design Each participant was presented with 18 conjoint
questions via an online survey. Each question provided
two choices of Personalised Trials that were defined
by up to eight attributes, including treatment types,
clinician involvement, study logistics and trial burden on
a patient.
Setting Online survey of adults with at least two common
chronic conditions in the USA.
Participants A nationally representative sample of
501 individuals were recruited from the Chronic Illness
Panel by Harris Poll Online. Participants were recruited
from several sources, including emails, social media and
telephone recruitment of the target population.
Main outcome measures The choice of Personalised
Trial design that the participant preferred with each
conjoint question.
Results There was large variability in participants’
preferences for the design of Personalised Trials. On
average, they preferred certain attributes, such as a short
time commitment and no cost. Notably, a population-level
analysis correctly predicted 62% of the conjoint responses.
An empirical Bayesian analysis of the conjoint data, which
supported the estimation of individual-level preferences,
improved the accuracy to 86%. Based on estimates of
individual-level preferences, patients with chronic pain
preferred a long study duration (p≤0.001). Asthma patients
were less averse to participation burden in terms of data-
collection frequency than patients with other conditions
(p=0.002). Patients with hypertension were more cost-
sensitive (p<0.001).
Conclusion These analyses provide a framework
for elucidating individual-level preferences when
implementing novel patient-centred interventions. The
data showed that patient preference in Personalised Trials
is highly variable, suggesting that individual differences
must be accounted for when marketing Personalised Trials.
These results have implications for advancing precise
interventions in Personalised Trials by indicating when
rigorous scientific principles, such as frequent monitoring,
is feasible in a substantial subset of patients.

Strengths and limitations of this study
►► This large online conjoint survey leveraged a rigor-

ously assembled panel by Harris Poll Online.
►► We surveyed a nationally representative sample for

age, gender, race/ethnicity, socioeconomic status
and geography in the USA.
►► The individual-level analyses took advantage of an
empirical Bayesian procedure that borrowed information from across individuals.
►► Utilities in conjoint analysis are interpreted relatively among the attributes included in the survey, and
cannot be interpreted in any absolute sense.
►► Generalisability of our findings might be limited to
patients with two or more chronic conditions predefined in the study.

Introduction
When managing chronic diseases and conditions, patients commonly try different treatments over time before finding the ‘right’
treatments for them. Personalised Trials, also
known as N-of-1 trials, aim to facilitate this type
of patient-centred experimentation. Contrast
to the conventional randomised clinical
trials where each participant is randomised
once to a single treatment, Personalised
Trials randomise treatments to the patient in
multiple crossover periods using clinical trial
principles, such as blinding and ascertaining
ecological outcomes.1 2 These methods are
particularly suitable for identifying long-term
treatments for chronic conditions for which
treatment effects are heterogeneous across
patients and thus require individualised treatments.3 In a series of demonstration trials,
Personalised Trials led to valuable changes in
treatment, cessation of treatment or confirmation of the original treatment.4–8 Due to
its pragmatic nature, the practice of Personalised Trials may provide individual patients
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with the best evidence about their treatment choices. As
a result, some have placed Personalised Trials at the top
of the methodological hierarchy of evidence-based medicine for informing treatment decisions.4 Recently, there
has been renewed interest in using Personalised Trials
for a variety of conditions,9–12 however, their clinical practice remains scattered due, in part, to insufficient patient
acceptability and demand.13–15
With a goal of increasing the adoption of Personalised
Trials into clinical practice, we developed a ‘collaboratory’
comprising a diverse pool of stakeholders—including
patients—relevant to the design and implementation of
Personalised Trials.16 Under the guidance of the collaboratory, we conducted an online conjoint survey in a
representative sample of adults with chronic conditions
who reside in the USA. In a primary analysis, which ascertained patient preferences for the design of Personalised
Trials, we identified significantly positive utilities for
Personalised Trials that would impose no out-of-pocket
costs on patients and for those that would require a short
time commitment for daily self-tracking.17 These findings
generally reflect that the average patient prefers Personalised Trials that are less burdensome in terms of cost and
time commitment. They also provide useful information
on design acceptability on a population level. However,
the degree to which individual-level preferences are driving
acceptability of Personalised Trials remains unknown.
Conjoint surveys are a well-
established method for
assessing product acceptability in market research and
economics, and more recently, for assessing patient preferences in healthcare at the population level.18–22 Recent
interest in precision medicine has increased the focus on
elucidating patient preferences at both the population
and individual levels. While heterogeneity of treatment
effects in the population motivates Personalised Trials,
heterogeneity in individual preferences of attributes for
Personalised Trials may be critical to explaining acceptability and improving dissemination of this approach.
In this article, we used the full conjoint data to assess
variations in individual-level preferences for the design
of Personalised Trials and to identify subpopulations of
patients according to their preferences.

Table 1 Design attributes of Personalised Trials
Domain

Design
attributes

Clinician
involvement

Treatment
selection

Trial conduct

Levels
►► Patient chooses

treatments to compare
in the study
►► Clinician chooses
treatments to compare
in the study
►► Study is conducted
without clinician
involvement
►► Study is conducted
with clinician
involvement

Treatment

Type of
treatment

►► Prescription medication
►► Lifestyle change
►► Complementary

Burden of
participation

Time
commitment

►► 5 min per day
►► 30 min per day

Data collection
frequency

►► Once per day
►► Three times per day

Study duration

►► 2 weeks
►► 12 weeks

alternative medicine

Patient burden Out-of-pocket
cost

Logistics

Blinding

►► No cost (all costs,

including travel, are
covered)
►► US$100
►► The study is not blinded
►► The study is blinded

Methods
Survey development
We designed an online survey study by engaging stakeholders through a Personalised Trial collaboratory.
This collaboratory consisted of 30 members, including
patients with multiple comorbidities, clinicians with and
without experience conducting N-of-1 trials, healthcare
administrators, scientists, methodologists/statisticians,
ethicists and experts in dissemination. Between July 2014
to September 2017, the collaboratory met quarterly to
review the study design, conduct, analysis and dissemination/interpretability. Collaboratory meetings were
conducted by phone and in person, and they were scheduled to maximise the availability of all participants. This

approach fostered a transparent process and helped to
improve the relevance of the study question. To inform
survey development, we first conducted focus groups with
providers (n=24) and patients (n=54) to understand attitudes toward Personalised Trials and design features.23 24
We then conducted an initial survey and literature review
to identify the key design attributes that could be
informed by patient preferences (eg, blinding, intensity
of self-tracking, extent of clinician involvement).
As part of a second survey, each participant answered
18 choice-
based conjoint questions that simulated the
selection of a Personalised Trial. Each question prompted
participants to select which prototype they preferred in
two hypothetical trial prototypes with up to eight design
attributes (table 1). Of the 18 conjoint questions, 15 used
a short format in which participants chose between two
hypothetical trials that differed by only two attributes
(eg, no-cost and long-duration trial vs some-cost and low-
duration trial) (figure 1). The remaining three conjoint
questions used a long format in which participants chose
between two hypothetical trials that differed across all
eight attributes at once (figure 2). We tested for interactions between attributes in our previous work, considering only data from the three long-format questions, and
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Figure 1 Example of a short-format question shown to a
participant in the online survey. This screenshot presents
two attributes (study duration and cost) in each of the two
hypothetical trials (option A and option B).

we did not find any evidence.17 In the present analysis,
in which we were interested in identifying individual-level
preferences, we used data from all 18 questions per individual. We developed a statistically efficient design using
Sawtooth Choice-
Based Conjoint software (Sawtooth,
2010) to generate a pool of 60 conjoint questions (45
short and 15 long). For the short questions, each attribute appeared with other attributes in the same question
at least once to allow for direct contrast. The method
for generating the long-format questions was similar to
that previously reported.17 In all, each participant was
randomly assigned 18 conjoint questions, 15 of which
were drawn from the 45 short questions and 3 from the
15 long questions. In addition to conjoint questions, we
collected data on the survey participants’ demographics
and diagnosis of chronic disease. The survey used in the
study is provided in online supplementary file 1.
Patient public involvement
Fifty-four patients were involved in the development of
the initial survey through the collaboratory and focus
groups. This process helped informed how we defined
the parameters in the conjoint survey.
Study participants
We conducted the survey among 501 participants who
were at least 18 years old, resided in the USA and reported

having two or more chronic diseases from a list of six
diseases (asthma, osteoporosis, depression, diabetes,
hypertension and hyperlipidaemia). This eligibility list
of diseases reflected a mix of symptomatic, asymptomatic and mental health conditions that are among the
most highly prevalent and burdensome in the USA.25 26
Recruitment of the participants was achieved through
a general population panel maintained by Harris Poll
Online (HPOL), which includes several million online
members. The HPOL panel was recruited from several
sources, including targeted emails sent by online partners,
social media, news and telephone recruitment of targeted
populations. Each recruitment source was carefully vetted
through a rigorous interviewing and testing process and
then continually monitored for response quality. For the
present study, the HPOL database of respondent information was actively screened and updated along with
numerous demographic and psychographic variables to
allow for precision in the online sample provided. These
sampling procedures have been widely used and support
a rigorous, scientifically acceptable practice without
spending considerable time and energy assembling large,
comprehensive samples.27 To reach the target sample
size and achieve a representative sample with at least two
chronic diseases,28 we screened and invited 15 883 potentially eligible individuals from the HPOL to participate in
the study via email. Details about sample size determination and participant inclusion were reported previously.17
All participants provided informed consent via e-signature. Only those participants at least minimally interested
in participating in a Personalised Trial for hypertension,
hyperlipidaemia, diabetes, depression, arthritis/joint
pain, breathing problems/bronchitis/asthma, back pain
or sleeping problems/insomnia completed the survey.
These patient conditions were the highest-
ranked,
patient-
preferred conditions and deemed appropriate
for Personalised Trials in our prior research. The cohort
selection and participant characteristics are described in
a previous report.17

Figure 2 Example of a long-format question shown to a
participant in the online survey. This screenshot presents
eight attributes in each of the two hypothetical trials (option A
and option B).

Statistical analysis
Estimating individual-level utilities and preferences
Individual patient preferences for different attributes
of Personalised Trials were estimated using empirical
Bayesian latent utility modelling on all conjoint responses
of the participants. Details of the model are given in
online supplementary file 2. Briefly, under this model,
the latent utility of trial prototype j to a participant i
(denoted as uij ) was postulated to follow a logistic distribution in which the mean depended on a linear combination of trial attributes. Specifically, having uij = βiT xij + εij ,
where εij is a standard logistic error and the design xij indicated the presence/absence of attributes in prototype j
presented to the participant. The coefficient βi  captured
the individual-level utility of participant i and was estimated
by the posterior mode assuming a mean zero normal
prior on βi  . We circumvented the subjectivity of postulating the prior variance-covariance matrix by estimating
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the matrix empirically using the marginal likelihood.29
For each attribute, a participant was indicated to have a
positive or negative preference if the estimated individual
utility was positive or negative, respectively. The reliability
of the estimate for individual-level utilities depended on
the number of questions answered per participant. Thus,
we excluded from the analysis those who answered 16 or
fewer of the 18 questions.
In addition, we fitted a latent utility model at a population level to all conjoint responses. This model assumed
no individual deviations from the population average
and set βi = β  for all participants. Under this population
model, every individual would be estimated to have the
same preference for a given attribute.
The benefits of accounting for individual preferences
were assessed by comparing the classification rates of
correct responses in the personalised and population-
level models. Correlations among the design attributes
were explored graphically and using Pearson correlation
coefficients based on the individual-
level utilities estimated by the personalised model.
Sample segmentation
We recorded the following baseline characteristics for
each participant and summarised them as categorical
variables: age (younger than 65 years vs 65 years or older),
sex (male vs female), race/ethnicity (non-Hispanic white
vs others), income (less than US$35 000 vs US$35 000
or more), education (some college or more vs less than
college), work status (employed full-time/part-time vs not
employed), insurance status (with vs without insurance)
and region of residence (Northeast vs South vs Midwest
vs West). Associations between these characteristics and
individual preferences were summarised using contingency tables and tested using χ2 tests; two-sided p values
were reported. As exploratory analyses, we also compared
the variability of individual-level utilities by these characteristics using Bartlett’s test, and we displayed the utility
distributions in graphs.
We also considered the following chronic conditions
in the analysis: joint pain, asthma, back pain, depression,
diabetes, hypertension, hyperlipidaemia and insomnia.
We asked whether a participant had a given condition;
those who had the condition were asked to indicate their
interest in participating in Personalised Trials. Association between chronic conditions and individual preferences were analysed in the same manner as above.

Table 2 Participant characteristics and conditions
Characteristics N (%)

Conditions

N (%)

Age
 65 or above

182 (36%)

Joint pain
 Yes

215 (43%)

 Below 65

318 (64%)

 No

285 (57%)

Sex

Asthma

 Male

222 (44%)

 Yes

149 (30%)

 Female

278 (56%)

 No

351 (70%)

Race/ethnicity

Back pain

 Non-Hispanic 341 (68%)
whites

 Yes

177 (35%)

 Others

 No

323 (65%)

159 (32%)

Education

Depression

 College or
more

400 (80%)

 Yes

210 (42%)

 Less than
college

100 (20%)

 No

290 (58%)

230 (46%)

 Yes

180 (36%)

 Not employed 270 (54%)

 No

320 (64%)

Income

Hypertension

 US$35 000 or 309 (62%)
above

 Yes

371 (74%)

 Below
US$35 000

 No

129 (26%)

Work status
 Employed
(full-time/
part-time)

Diabetes

191 (38%)

Insurance
 Have
insurance
 No insurance

Hyperlipidaemia
452 (90%)

 Yes

270 (54%)

48 (10%)

 No

230 (46%)

Region
 Northeast

Insomnia
86 (17%)

 Yes

121 (24%)

 South

194 (39%)

 No

379 (76%)

 Midwest
 West

116 (23%)
104 (21%)

 
 

Results
Population-level utilities
Among the 501 survey participants, most (n=497)
answered all 18 conjoint questions and three answered 17
questions (14 short-format, 3 long-format). One participant who answered all 15 short questions but not the
long questions was excluded from the analysis. Thus,
we estimated the utilities in 500 participants with a total
of 8997 conjoint responses (1500 long-format and 7497

short-
format) from the participants recruited through
HPOL. Table 2 describes the participant characteristics
and gives the distribution of the chronic conditions.
Table 3 presents the estimated utilities of trial design
attributes according to the population-level model, along
with the 95% CIs. The analysis that used only the long-
format questions identified two statistically significant
attributes preferred by the participants on a population
level: requiring short (5 min) time commitment (utility
difference=0.16; p=0.015) and having no cost (utility
difference=1.52; p<0.001). The analysis using all conjoint
questions confirmed the findings for these two attributes
with greater precision. It also revealed that participants
preferred complementary alternative medicine (CAM)
over prescription medication (utility difference=0.15;
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Table 3 Population-level utilities for design attributes of Personalised Trials
Utility (95% CI)
Long-format questions only All questions
(n=1500)
(n=8997)

Attribute description
Patient lets clinician choose treatments instead of choosing own
Study is conducted with clinician involvement instead of without

0.03 (-0.10 to 0.17)
0.11 (-0.02 to 0.25)

−0.01 (-0.10 to 0.07)
0.17 (0.09 to 0.25)*

Treatment is lifestyle change instead of prescription medication

0.02 (-0.17 to 0.21)

−0.14 (-0.24 to -0.05)*

Treatment is CAM instead of prescription medication

0.15 (-0.04 to 0.34)

0.15 (0.06 to 0.24)*

Study requires 5 min commitment daily instead of 30 min

0.16 (0.03 to 0.30)*

0.42 (0.34 to 0.50)*

Study collects data one time per day instead of three times per day

0.08 (-0.06 to 0.21)

0.34 (0.25 to 0.42)*

Study lasts 2 weeks instead of 12 weeks

0.05 (-0.09 to 0.18)

0.00 (-0.09 to 0.09)

1.52 (1.39 to 1.66)*
−0.08 (-0.22 to 0.05)

1.40 (1.30 to 1.50)*
−0.34 (-0.42 to -0.25)*

Study has no cost instead of costing US$100
Study is blinded instead of not being blinded
*P<0.05, indicated by 95% CIs excluding zero.
CAM, complementary alternative medicine.

p=0.001), which was preferred over lifestyle changes
(utility difference=0.14; p=0.002), and to have clinician
involvement (vs no involvement) during the study (utility
difference=0.17; p<0.001). We also found that a low
frequency of data collection had a positive utility (utility
difference=0.34; p<0.001) and blinding had a negative
utility (utility difference=−0.34; p<0.001).
In summary, the population-level analysis depicted that
participants favoured Personalised Trials with an experiment of CAM and clinician supervision in an unblinded
fashion. They also preferred a low level of burden in terms
of time commitment and data-collection frequency, as
well as no out-of-pocket cost. Using this typified protocol
would yield a 62% correct prediction in all 8997 conjoint
responses, while randomly guessing a response would
yield 50%.
Individual-level utilities
Several participants had preferences that deviated from
the population results shown above. Twelve per cent
(n=59) of the participants preferred bearing out-
of-
pocket costs, 18% (n=91) preferred a long daily time
commitment and 16% (n=78) preferred a frequent data-
collection schedule (table 4). The cohort’s average preference was skewed towards not being blinded during a trial,
although to a lesser extent (30% preferred blinding).
The preferences for the other design attributes (eg, study
duration) were relatively evenly distributed, suggesting
heterogeneity in preferences among the participants.
Figure 3 demonstrates the variations in the numerical
individual-level utilities for design attributes according to
the personalised model. For example, while most participants had a strong positive preference for no cost (ie,
having a positive utility vs US$100 cost), some individuals had large negative utility for bearing no cost. Similarly, while the whole population had a negative utility
on blinding, some individuals had positive utilities for
blinding.
Cheung YK, et al. BMJ Open 2020;10:e036056. doi:10.1136/bmjopen-2019-036056

Using these estimated individual-
level utilities based
on the personalised model to predict responses in the
conjoint survey would yield an 86% correct prediction
in all 8997 responses. This result is a marked increase of
24 percentage points above the population-level analysis.
There was a strong correlation between utilities
for clinician involvement during a study and a clinician choosing the treatments when planning the study
(correlation=0.96; p<0.001; figure 4A). Attributes related
to burden of participation were correlated: participants
who had high utilities for short daily time commitment
tended to have high utilities for fewer data collections
per day (correlation=0.87; p<0.001; figure 4B), for short
study duration (correlation=0.20; p<0.001; figure 4C)
and for not paying out-of-pocket costs (correlation=0.69;
p<0.001; figure 4D). Preferences for medication and
CAM compared with lifestyle change were statistically
associated with preference for blinding: the correlation
with utilities for blinding was 0.28 (p<0.001) for utilities
for medication over lifestyle change, and 0.36 (p<0.001)
for utilities for CAM over lifestyle change.
Association between individual-level preferences and
demographics
Of the male participants, about 60% preferred a clinician
choosing the treatment (online supplementary table S1
in online supplementary file 3) and being involved in
conducting the trial (online supplementary table S2),
while 53% were estimated to prefer prescription medication (online supplementary table S3). The preferences
among female participants on these attributes were relatively evenly distributed.
Race/ethnicity groups other than non-Hispanic whites
were less averse to participation burden (ie, time commitment, data-
collection frequency, study duration and
out-of-pocket cost) compared with non-Hispanic whites
(online supplementary tables S4–S7), although the whole
cohort would prefer less burden.
5
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Table 4 Individual preferences for attributes of
Personalised Trials

Attribute description

Number of
participants
(%)

Treatment selection
 Prefer patient choosing treatments

235 (47%)

 Prefer clinician choosing treatments

265 (53%)

Trial conduct
 Prefer no clinician involvement during
study

226 (45%)

 Prefer clinician involvement during study

274 (55%)

Treatment types
 Prefer prescription medications

209 (42%)

 Prefer lifestyle change

123 (25%)

 Prefer CAM

168 (34%)

Patient burden/commitment
 5 min daily

409 (82%)

 30 min daily

91 (18%)

Data-collection frequency
 One time per day
 Three times per day

422 (84%)
78 (16%)

Study duration
 2 weeks

243 (49%)

 12 weeks

257 (51%)

Out-of-pocket costs
 None
 US$100

441 (88%)
59 (12%)

Blinding
 Prefer not blinding
 Prefer blinding

352 (70%)
148 (30%)

Figure 3 Distribution of individual-level utilities for different
attributes. The vertical red lines indicate the average utility in
the cohort. CAM, complementary alternative medicine.

preference for high data-collection frequency (variance
ratio=1.45; p=0.005; figure 5E) and out-of-pocket costs
(variance ratio=1.72; p<0.001; figure 5F).
Education was associated with treatment types: participants with a college education or more preferred
prescription medication, whereas the others preferred
CAM (online supplementary table S3).
Insurance status and region of residence did not
correlate with any preferences in design attributes. No

CAM, complementary alternative medicine.

Participants younger than 65 years were overall less
averse to participation burden than the older group
(except for study duration). In addition, the younger
participants demonstrated greater variability in their utilities for data collection frequency (variance ratio=1.32;
p=0.040; figure 5A) and cost (variance ratio=1.48;
p=0.004) than the older participants, resulting in some
outlying values favouring high burden (figure 5B).
Participants who were employed were less averse to
costs (online supplementary table S7) and high frequency
of data collection (online supplementary table S5) than
those who were unemployed. They also demonstrated
greater heterogeneity in their preferences for these attributes with variance ratios 2.07 (p<0.001; figure 5C) and
1.66 (p<0.001; figure 5D), respectively. Participants with
high income were less averse to bearing some out-of-
pocket costs than those with low income (online supplementary table S7), with greater heterogeneity in their

Figure 4 Correlations of individual-level utilities for some
attributes.
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the variability in preferences for design attributes in
Personalised Trials. Using empirical Bayesian estimation,
we assessed the individual-
level utilities of the design
attributes in the cohort. We found that the personalised
model would improve on prediction of response to participation in Personalised Trials in a population-level model.

Figure 5 Distribution of individual-level utilities for data-
collection frequency (top) and out-of-pocket cost (bottom) by
age, employment status and income.

association was found between preference for blinding
and any demographics, suggesting blinding was consistently undesirable across the demographic spectrum
(online supplementary table S8).
Association between individual-level preferences and chronic
conditions
Patients with diabetes (and to a lesser extent those with
hyperlipidaemia) preferred clinician involvement (online
supplementary tables S9 and S10). In addition, diabetic
patients with interest in Personalised Trials preferred
medications compared with the other groups (online
supplementary table S11).
Patients with asthma preferred no clinician involvement (online supplementary table S10). They were less
averse to participation burden in terms of daily time
commitment (online supplementary table S12) and data-
collection frequency (online supplementary table S13),
although no difference was noted for study duration
(online supplementary table S14). A larger percentage of
asthma patients preferred out-of-pocket cost compared
with other patients (online supplementary table S15). In
particular, participants with hypertension were more cost-
sensitive than those with other conditions (online supplementary table S15).
Participants with joint pain or back pain who were interested in participating in a Personalised Trial preferred a
long study duration (online supplementary table S14),
but were also much less willing to bear costs compared
with those without the diagnosis (online supplementary table S15).
None of the patient conditions were correlated with
blinding (online supplementary table S16).
Discussion
In this article, we analysed a conjoint survey conducted in
a representative sample of patients with multiple chronic
conditions living in the USA and aimed to understand
Cheung YK, et al. BMJ Open 2020;10:e036056. doi:10.1136/bmjopen-2019-036056

Comparison of findings
Our analysis offers important insights into the heterogeneity in preferences among individuals and suggests the
need to personalise design features of Personalised Trials,
including attributes that were deemed or thought to be
undesirable. For example, while focussing on minimal
time commitment and cost may be the best marketing
approach based on the population-level analysis, we identified small segments in the cohort that were less averse to
out-of-pocket costs (eg, high income, asthma) and long
daily time commitment (eg, younger). The implication
on practice is even greater for attributes with marked
heterogeneity, such as study duration. Because one-half
of the cohort preferred a short study duration and the
other half preferred long duration, it may be beneficial to
market the study duration based on patient preference.
Our results also provide trialists of pain studies based on
insights that long study trials are generally acceptable and
even preferred among patients with chronic joint pain
or back pain. Overall, our findings suggest that for those
attributes with marked heterogeneity, the best approach
may be to allow patients to design their own trials (eg,
around treatment options, level of clinician involvement)
to maximally improve acceptability and uptake of Personalised Trials.
We also confirmed our previous descriptive analysis
and showed that out-of-pocket costs and long daily time
commitment were two major deterrents of participation
in Personalised Trials when averaged across patients.
By using the full conjoint data (short and long questions, not only long questions), we also found additional
undesirable attributes. For example, blinding negatively
affected interest in participating in Personalised Trials at
the population level (table 3). Our results are consistent
with studies showing that blinding is a strong negative
driver of patient decision-
making regarding participation in clinical trials.30 31 On the other hand, our analyses of the individual preferences indicated that almost
30% of the participants actually preferred blinding as
a design feature (table 4). This trend was quite robust
across demographics and chronic conditions (online
supplementary tables S8 and S16). Thus, our results
suggest that providers and researchers may want to design
trials in which blinding is optional in order to reach the
maximum number of patients. This is particularly true for
trials involving lifestyle change where blinding may not
be feasible in the first place. Scientific validity in these
settings should be further scrutinised by measuring and
studying the underlying mechanisms of action (eg, self-
efficacy). On the other hand, it is interesting to note that
participants who preferred medication or CAM were less
7
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averse to blinding. Therefore, blinding might still be a
feasible choice to explore among patients who chose to
test medication and CAM.
Clinical implications
Personalised Trials are designed to help a patient and
his or her clinician make healthcare decisions that are
informed by high-
integrity, evidence-
based information that is uniquely relevant to that patient’s preferred
outcomes and values. However, in the past, patients have
not been willing to engage in these trials. Consequently,
this powerful approach is almost never used. Only 108
series of Personalised Trials have been published,15 a
marked dearth compared with other research methods.
Major barriers to implementing Personalised Trials
include a lack of knowledge about the conditions, treatments and outcomes for which patients would view such
trials as beneficial; lack of design features that have been
widely agreed on and would be acceptable to patients
considering involvement in a Personalised Trial and poor
understanding of patient tolerance for outcome assessment and burden.23 32
Our findings support the implementation of Personalised Trials by providing information about the
conditions and characteristics associated with greater
acceptance of these trials, especially when combined with
the use of technology. They also suggest useful strategies
for improving uptake in select populations. For example,
we found that asthma patients were more open to a
greater frequency in data collection during a day, which
might be best facilitated by smartphone and mobile technologies that automate daily collection and alleviate the
burden on outcome assessments.33–35
Strengths, limitations and future research
Our survey leveraged the panel assembled and maintained by the rigorous Harris Poll Online and was
performed in a cohort representative for age, gender,
race/ethnicity, socioeconomic status and region of residence in the USA. The 18 questions in the conjoint
survey were completely answered in all but four participants, giving reliability in the assessment of individual-
level preference for the eight design attributes, and
resulting in new insights beyond our previous report
that focussed on design acceptability at a population
level. In addition, the empirical Bayesian procedure
facilitated borrowing information from across individuals, and yielded stable computational results when estimating the individual utilities. The correlation among
utilities for certain attributes and demographic variables demonstrated high level internal consistency.
Despite the strengths in the survey design and
conduct, this study has a few limitations. First, the
generalisability of our findings might have been limited
by the eligibility criteria that included only participants
with two or more predefined chronic conditions. In
addition, due to the online survey methodology, our
sample consisted of those with Internet access and those
8

who could self-report the symptoms of their conditions.
However, as we created the list of chronic conditions
using a careful process involving focus groups and
national survey, these conditions captured the most
common and burdensome symptomatic and asymptomatic conditions in the USA. Furthermore, the cohort
was sampled to achieve the demographic, geographic
and socioeconomic diversity representative of the USA.
Second, the individual-level analysis was performed
as an exploratory analysis to describe the heterogeneity
in the population. As a result, the number of conjoint
questions as well as the survey sample size were not
determined a priori to ensure adequate precision in
this analysis. Specifically, the sample size would not be
adequate to assess the interaction of chronic conditions on preference differences. For example, only 28
participants with asthma and hypertension indicated
they were very interested in participation in an asthma
Personalised Trial and a hypertension Personalised
Trial. Our study data might however suggest the more
prevalent comorbidity combinations for further investigation. Third, the attributes and the levels of attributes
considered in the survey was not disease specific. As a
result, some of the levels might not be ideally defined;
for example, 12 weeks might not be considered a long
study in the asthma population. Fourth, our analyses
were not designed to assess the relationship between
attributes and actual behaviour around or acceptance
for a Personalised Trial protocol in the survey, as the
conjoint choice-based questions aimed to elicit implicit
relative utilities for different levels of attributes in
the protocol and to identify important attributes for
personalisation. While disseminating the results to
the online study participants is not applicable, future
research should focus on testing whether including
these individual preferences in a Personalised Trial
design will increase acceptability by the patients and
facilitate dissemination and integration into clinical
practice.

Conclusions
In the true spirit of Personalised Trials, we sought to
ascertain individual variability in preferences for the
design of Personalised Trials. Incorporating individual
preferences may improve willingness to participate in
Personalised Trials. Our study also provides a framework for elucidating the degree to which individual-
level (vs population-level) factors drive willingness and
behaviour, with widespread implications for improving
the uptake of other patient-
centred evidence-
based
innovations and programmes. Just as Personalised
Trials are intended to best match patients with effective treatments, understanding individual preferences
for Personalised Trials is an equally important consideration for matching the design of a Personalised Trial
with a patient’s preference.
Cheung YK, et al. BMJ Open 2020;10:e036056. doi:10.1136/bmjopen-2019-036056
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